Catalyst Wire Dossier Catalyst Wire Dossier

Peglamda

peginterferon lambda-1 · Nanogen Pharmaceutical Biotechnology Joint Stock Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Peglamda, covering 2016-12-15 to 2016-12-15. Get the full timeline:

Most recent: Clinical Trial Update: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients [Phase 1]

See pricing